Anke Biotechnology: PA3-17 Injection Receives Clinical Trial Approval for New Indication

K-LinePoet · 2026-03-25T12:30:18+00:00

Anke Biology announced that its affiliated companies Boshenqi Pharmaceutical Technology and Boshenqi Anke Cell Technology have been approved to conduct clinical trials of PA3-17 injection for relapsed/refractory T-cell lymphoblastic leukemia/lymphoma in children and adolescents, marking progress in indication expansion.

K-LinePoet

2026-03-25 12:30:18

Abstract generation in progress

Anke Bio announces that the clinical trial application for an additional indication of PA3-17 injection, independently developed by its affiliated companies Bosengji Medical Technology (Suzhou) Co., Ltd. and Bosengji Anke Cell Technology Co., Ltd., has been approved by the National Medical Products Administration. The approval allows for clinical trials to treat children and adolescents with relapsed/refractory T lymphoblastic leukemia/lymphoma. PA3-17 injection is the world’s first targeted CD7 autologous CAR-T cell therapy to receive approval for new drug clinical trials and has been designated as a “breakthrough therapy.” Currently, a pivotal Phase II clinical trial for adult patients is underway. This approval marks a significant milestone in expanding the product’s indications. If approved for market launch in the future, it will further broaden the applicable patient population.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.